Journal
BRAIN RESEARCH BULLETIN
Volume 86, Issue 1-2, Pages 22-28Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.brainresbull.2011.07.001
Keywords
Doxorubicin; Epicatechin; Tumor necrosis factor alpha (TNF-alpha); Inducible NOS (iNOS); Nuclear factor kappa B (NF-kappa B)
Categories
Ask authors/readers for more resources
Doxorubicin (DOX) is considered one of the most important chemotherapeutic agents that is used for the treatment of solid tumors. Its long-term use can cause neurodegenerative disorders due to its prolonged activation of microglia. The present study proved that the use of epicatechin prior to DOX treatment significantly attenuated not only the increase in TNF-alpha, iNOS and NF-kappa B expressions but also the increase in TNF-alpha and total nitrite levels in brain tissue when compared with rats treated with DOX-only. Thus, our study revealed that epicatechin can be used for the treatment of neuroinflammation and also for preventing the development of neurodegenerative disease during antineoplastic therapy because of its protective role in attenuation of neurotoxic pro-inflammatory mediators including TNF-alpha, NF-kappa B, and iNOS. (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available